| Alzheimer's Disease
Kisunla vs Leqembi
Side-by-side clinical, coverage, and cost comparison for alzheimer's disease.Deep comparison between: Kisunla vs Leqembi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLeqembi has a higher rate of injection site reactions vs Kisunla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Leqembi but not Kisunla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kisunla
Leqembi
At A Glance
IV infusion
Every 4 weeks
Anti-amyloid beta mAb
IV infusion
Every 2 weeks
Anti-amyloid beta antibody
Indications
- Alzheimer's Disease
- Alzheimer's Disease
Dosing
Alzheimer's Disease Escalating IV infusion over approximately 30 minutes every 4 weeks: 350 mg (infusion 1), 700 mg (infusion 2), 1,050 mg (infusion 3), 1,400 mg (infusion 4 and beyond); consider stopping based on reduction of amyloid plaques to minimal levels on amyloid PET imaging.
Alzheimer's Disease Starting dosage: 10 mg/kg IV infusion once every 2 weeks over approximately one hour; maintenance dosage: 10 mg/kg IV infusion once every 4 weeks or 360 mg SC injection once weekly via autoinjector.
Contraindications
- Known serious hypersensitivity to donanemab-azbt or any excipient, including anaphylaxis
- Serious hypersensitivity to lecanemab-irmb or any excipient of LEQEMBI or LEQEMBI IQLIK (reactions include angioedema and anaphylaxis)
Adverse Reactions
Most common (>=5%) ARIA-H microhemorrhage, ARIA-E, ARIA-H superficial siderosis, headache, infusion-related reaction
Serious Hypersensitivity reactions (including anaphylaxis), intestinal obstruction, intestinal perforation, ARIA-E, ARIA-H
Most common (>=5%) Infusion-related reactions, ARIA-H, ARIA-E, headache, superficial siderosis of CNS, rash, nausea/vomiting, cough, diarrhea
Serious Amyloid related imaging abnormalities (ARIA-E, ARIA-H), hypersensitivity reactions, infusion-related reactions
Pharmacology
Donanemab-azbt is a humanized IgG1 monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta; it reduces amyloid beta plaques in the brain, a defining pathophysiological feature of Alzheimer's disease.
Lecanemab-irmb is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, reducing amyloid beta plaques in the brain - a defining pathophysiological feature of Alzheimer's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kisunla
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
Leqembi
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Kisunla
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Leqembi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kisunla
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Leqembi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Kisunla Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Leqembi Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KisunlaView full Kisunla profile
LeqembiView full Leqembi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.